Compare TKO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TKO | ABVX |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 11.9B |
| IPO Year | 2023 | 2022 |
| Metric | TKO | ABVX |
|---|---|---|
| Price | $184.40 | $113.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $224.53 | $131.31 |
| AVG Volume (30 Days) | ★ 1.1M | 818.6K |
| Earning Date | 05-06-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ 11200.00 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $4,735,151,000.00 | N/A |
| Revenue This Year | $23.14 | $52.14 |
| Revenue Next Year | $1.05 | $4,132.27 |
| P/E Ratio | $74.93 | ★ N/A |
| Revenue Growth | ★ 68.85 | N/A |
| 52 Week Low | $176.00 | $69.81 |
| 52 Week High | $226.94 | $148.83 |
| Indicator | TKO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 38.86 |
| Support Level | $180.23 | $107.67 |
| Resistance Level | $190.19 | $129.00 |
| Average True Range (ATR) | 5.25 | 3.46 |
| MACD | -1.10 | -0.85 |
| Stochastic Oscillator | 6.27 | 7.56 |
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four activities: Media rights, production, and content, Live events and hospitality, Partnerships and marketing and Consumer products licensing, The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.